COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu

Breath Test for Patients With Acute Liver Disease for Early Detection of the Need for Transplant or Recovery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01435421
Recruitment Status : Unknown
Verified September 2011 by Hadassah Medical Organization.
Recruitment status was:  Not yet recruiting
First Posted : September 16, 2011
Last Update Posted : September 16, 2011
Information provided by (Responsible Party):
Hadassah Medical Organization

Brief Summary:

Acute liver failure (ALF) results from an abrupt loss of hepatic metabolic and synthetic function and leads to encephalopathy and potentially multi-organ dysfunction. Aetiologies include autoimmune and metabolic diseases, infectious agents and hepatotoxins. Worldwide, infectious hepatitis (A, B and E) is the most common cause. In Western Europe and the USA, ALF is most frequently caused by paracetamol intoxication.

The MBT can produce immediate results to aid in decision making in patients with acute liver disease. Such a test may affect decision-making regarding transplantation in this setting, facilitate appropriate discharge from critical care to other hospital units and to home, provide point of care assessment of therapeutic interventions.

The BreathID can potentially help in determining:

  • Parameter to include patients in transplant list (the UNOS 1A group)
  • Identification that patient deteriorates and needs extended hospitalization/referral to ICU/change in management
  • An addition to the MELD and or other scores to estimate risk in other acute patients
  • Additional information to that of other commonly utilized prognostic scoring systems

The primary end-point of the study is to develop a model to predict deterioration of the liver disease, which incorporates measurements from the MBT along with other potential variables. The data collected will be used to develop a prediction model using data-mining methodology (linear and non-linear regression models, binary trees, neural networks, etc…). The predictive models may include measurements from the MBT, blood test results, as single measurements or as trend over time. The model that will be developed, will attempt to predict the disease deterioration vs. recovery accurately, at an earlier time point than the standard procedure. A threshold will then be determinate based on adequate sensitivity and specificity levels.

Condition or disease
Acute Liver Failure

Layout table for study information
Study Type : Observational
Estimated Enrollment : 112 participants
Official Title: Breath Test for Patients With Acute Liver Disease for Early Detection of the Need for Transplant or Recovery
Study Start Date : October 2011
Estimated Primary Completion Date : December 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Liver Diseases

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients that are hospitalaized.

Inclusion Criteria:

  1. Adult men or women (>18 years of age).
  2. Acute Liver insult
  3. No evidence of cirrhosis (unless clinical acute Wilsons)
  4. INR > 1.5
  5. Duration of illness < 24 weeks -

Exclusion Criteria:

  1. Patient with any chronic liver disease
  2. Patient has severe congestive heart failure
  3. Patient has severe pulmonary hypertension
  4. Patient has chronic renal insufficiency with severe cardiac disease
  5. Patient has previous surgical bypass surgery for morbid obesity
  6. Patient has extensive small bowel resection
  7. Patient with established extra-hepatic auto-immune disease on long term treatment
  8. Patient is a recipient of any organ transplant (within the last 3 months)- Patient with proven or suspected hepatocellular carcinoma
  9. Patient is pregnant
  10. Patient allergic to paracetamol (such as Tylenol or any other related medications)
  11. Patients in whom oral intake is contra-indicated
  12. Patient, based on the opinion of the investigator, should not be enrolled into this study
  13. Patients or their nominated representative is unwilling to sign informed consent
  14. Patients that are participating in other clinical trials evaluating experimental treatments or procedures, not including observatory trials -
Layout table for additonal information
Responsible Party: Hadassah Medical Organization Identifier: NCT01435421    
Other Study ID Numbers: ALF-BID-1108-HMO-CTIL
First Posted: September 16, 2011    Key Record Dates
Last Update Posted: September 16, 2011
Last Verified: September 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Liver Failure
Liver Failure, Acute
Digestive System Diseases
Hepatic Insufficiency